Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XPO1 | O14980 | 20/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12128329 | 1.00 | XPO1 (0.85) | XPO1 | |
| SCHEMBL1336042 | 1.00 | XPO1 (0.85) | XPO1 | |
| SCHEMBL12127163 | 0.92 | XPO1 (1.00) | XPO1 | |
| SCHEMBL15184830 | 0.92 | XPO1 (1.00) | XPO1 | |
| SCHEMBL15184831 | 0.92 | XPO1 (1.00) | XPO1 | |
| SCHEMBL12127076 | 0.91 | XPO1 (0.76) | XPO1 | |
| SCHEMBL1333830 | 0.89 | XPO1 (0.73) | XPO1 | |
| SCHEMBL1336205 | 0.89 | XPO1 (0.73) | XPO1 | |
| SCHEMBL1333829 | 0.89 | XPO1 (0.73) | XPO1 | |
| SCHEMBL12127171 | 0.85 | XPO1 (1.00) | XPO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140155370-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | Karyopharm Therapeutics Inc. | 2014-06-05 | — | — | US | claimed |
| EP-2542089-A1 | NUCLEAR TRANSPORT MODULATIORS AND USES THEREOF | Karyopharm Therapeutics, Inc. (US) | 2013-01-09 | — | — | EP | claimed |
| US-20110275607-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS, INC. (US) | 2011-11-10 | — | — | US | claimed |
| WO-2011109799-A1 | NUCLEAR TRANSPORT MODULATIORS AND USES THEREOF | KARYOPHARM THERAPEUTICS, INC. (US) | 2011-09-09 | — | — | WO | claimed |
| US-10202366-B2 | Methods of promoting wound healing using CRM1 inhibitors | Karyopharm Therapeutics Inc. (US) | 2019-02-12 | — | — | US | disclosed |
| US-9550757-B2 | Nuclear transport modulators and uses thereof | Karyopharm Therapeutics Inc. (US) | 2017-01-24 | — | — | US | disclosed |
| US-20160304500-A1 | Methods of Promoting Wound Healing Using CRM1 Inhibitors | Karyopharm Therapeutics Inc. | 2016-10-20 | — | — | US | disclosed |
| US-20140155370-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | Karyopharm Therapeutics Inc. | 2014-06-05 | — | — | US | disclosed |
| US-8513230-B2 | Nuclear transport modulators and uses thereof | KARYOPHARM THERAPEUTICS, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-20110275607-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS, INC. (US) | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202366-B2 | Methods of promoting wound healing using CRM1 inhibitors | XPO1, XPA, ERCC2 | XPO1 1/4885 |
| US-20140155370-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XPO1, NXF1, XPOT | XPO1 1/4885 |
| US-20110275607-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XPO1, NXF1, XPOT | XPO1 1/4885 |
| US-20160304500-A1 | Methods of Promoting Wound Healing Using CRM1 Inhibitors | XPO1, KEAP1, COL1A1 | XPO1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.